

Shuang-Jian Qiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8165676/publications.pdf>

Version: 2024-02-01

78
papers

3,465
citations

201674

27
h-index

168389

53
g-index

80
all docs

80
docs citations

80
times ranked

5240
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6212-6222.	7.0	1,012
2	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 β and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	17.0	150
3	Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. <i>Journal of Hematology and Oncology</i> , 2015, 8, 23.	17.0	136
4	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	7.0	112
5	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. <i>Gastroenterology</i> , 2014, 146, 1397-1407.	1.3	111
6	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	7.0	102
7	HNRNPAB Induces Epithelial \rightarrow Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i> . <i>Cancer Research</i> , 2014, 74, 2750-2762.	0.9	91
8	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	12.8	90
9	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 846-861.	1.8	84
10	HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. , 2019, 7, 77.		81
11	Lectin \rightarrow based glycoproteomics to explore and analyze hepatocellular carcinoma \rightarrow related glycoprotein markers. <i>Electrophoresis</i> , 2009, 30, 2957-2966.	2.4	69
12	Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. <i>Oncotarget</i> , 2014, 5, 7820-7832.	1.8	63
13	Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. <i>British Journal of Cancer</i> , 2016, 114, 767-776.	6.4	60
14	Circulating CD14 ⁺ HLA \rightarrow DR ^{low} myeloid \rightarrow derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , 2017, 47, 1061-1071.	3.4	56
15	Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. <i>Cell Death and Disease</i> , 2021, 12, 260.	6.3	56
16	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , 2016, 7, 70654-70668.	1.8	44
17	Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. <i>BMC Cancer</i> , 2014, 14, 297.	2.6	40
18	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 1540-1547.	1.7	40

#	ARTICLE	IF	CITATIONS
19	Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. <i>Oncotarget</i> , 2017, 8, 13293-13303.	1.8	39
20	Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. <i>Cell Reports</i> , 2016, 17, 2979-2993.	6.4	35
21	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , 2017, 22, 561-569.	3.7	35
22	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. <i>Oncotarget</i> , 2017, 8, 5135-5148.	1.8	35
23	Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-ROR1 \pm -Wnt/ β 2-Catenin axis. <i>Cancer Letters</i> , 2020, 476, 140-151.	7.2	34
24	Mitogen-activated protein kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial \rightarrow mesenchymal transition. <i>Hepatology</i> , 2015, 62, 1804-1816.	7.3	33
25	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 169-178.	1.5	32
26	Establishment of a hepatocellular carcinoma patient \rightarrow derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	5.1	32
27	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. <i>Surgery</i> , 2014, 156, 651-660.	1.9	31
28	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	6.3	31
29	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , 2019, 17, 106.	5.5	31
30	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 47121-47135.	1.8	29
31	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 5575-5584.	2.5	28
32	Positive α HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of α HBV-related HCC. <i>Liver International</i> , 2016, 36, 284-292.	3.9	27
33	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	2.5	27
34	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF κ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	4.0	27
35	Decreased Expression of GATA2 Promoted Proliferation, Migration and Invasion of HepG2 In Vitro and Correlated with Poor Prognosis of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e87505.	2.5	26
36	Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2018, 23, 1482-1493.	3.7	26

#	ARTICLE	IF	CITATIONS
37	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 487-487.	1.7	25
38	Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. <i>Journal of Cancer</i> , 2017, 8, 3862-3867.	2.5	23
39	Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. <i>Cell Reports</i> , 2017, 21, 1870-1882.	6.4	22
40	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 366, 112-122.	7.2	21
41	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , 2018, 18, 550.	2.6	20
42	Generation and characterization of a tetraspanin CD151/integrin $\alpha 6 \beta 1$ -binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. <i>Oncotarget</i> , 2016, 7, 6314-6322.	1.8	20
43	Combined preoperative albumin-bilirubin (ALBI) and serum γ -glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection. <i>Journal of Cancer</i> , 2019, 10, 4836-4845.	2.5	19
44	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	2.4	19
45	Shanghai Score. <i>Chinese Medical Journal</i> , 2017, 130, 2650-2660.	2.3	18
46	Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. <i>American Journal of Cancer Research</i> , 2015, 5, 450-7.	1.4	18
47	Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. <i>Oncotarget</i> , 2017, 8, 1774-1787.	1.8	17
48	A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection. <i>Journal of Surgical Oncology</i> , 2018, 117, 625-633.	1.7	16
49	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2018, 9, 1106-1112.	2.5	16
50	S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 19-30.	2.7	15
51	TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. <i>Digestive and Liver Disease</i> , 2020, 52, 668-676.	0.9	15
52	Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: a prognostic nomogram study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5383-5394.	1.9	14
53	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	2.5	14
54	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	2.8	14

#	ARTICLE	IF	CITATIONS
55	ROR-1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. <i>Cytokine</i> , 2020, 129, 155004.	3.2	14
56	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4094-4094.	1.6	14
57	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , 2015, 2, 231-244.	4.2	13
58	Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis. <i>Oncogene</i> , 2021, 40, 2910-2922.	5.9	13
59	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	2.6	12
60	Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 5187-5195.	1.9	12
61	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1301-1301.	1.7	11
62	High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>Journal of Cancer</i> , 2019, 10, 1313-1324.	2.5	9
63	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	3.7	9
64	Inflammation-nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 825-835.	2.2	8
65	BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. <i>Digestive and Liver Disease</i> , 2022, 54, 692-700.	0.9	8
66	Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 19.	1.8	8
67	Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 871769.	4.8	8
68	Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12867-12880.	2.0	7
69	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4099-4099.	1.6	6
70	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	3.1	6
71	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6281-6290.	2.0	5
72	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16163-e16163.	1.6	5

#	ARTICLE	IF	CITATIONS
73	MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β -catenin and predicts poor prognosis. <i>Liver International</i> , 2021, 41, 1409-1420.	3.9	4
74	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	1.6	3
75	Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2022, , .	1.8	3
76	Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. <i>Future Oncology</i> , 2019, 15, 3917-3934.	2.4	2
77	Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16158-e16158.	1.6	2
78	TM2D1 contributes the epithelial-mesenchymal transition of hepatocellular carcinoma via modulating AKT/ β -catenin axis. <i>American Journal of Cancer Research</i> , 2021, 11, 1557-1571.	1.4	1